Alle afleveringen
494 afleveringen, van nieuw naar oud
-
Swiss Biotech Day: Lausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria
6 mei 2025 · 10 min
CEO Klaus Dugi describes why the company is focused on mitochondria and how it using small molecules to fix them. He covers the three main disease areas Vandria is focused on, including a clinical program in mild cognitive impairment.
-
Swiss Biotech Day: Basel based BioVersys successfully completed an approximately CHF 80 million IPO in February to advance its work in antimicrobial resistance
6 mei 2025 · 11 min
Co-Founder & CEO Marc Gitzinger describes the success factors behind the IPO and walks us through the company's two lead programs. Plus, his thoughts on the evolving business model for this field.
-
Swiss Biotech Day: Zurich based LimmaTech Biologics is developing vaccines against antimicrobial resistant pathogens
5 mei 2025 · 8 min
CEO Franz-Werner Haas describes the rationale for developing vaccines for the antimicrobial space, he explains the company's E. coli based platform, and he walks us through the pipeline.
-
Swiss Biotech Day: Basel based Nouscom presented data at AACR last week on its cancer vaccine that is meant to lower the risk of Lynch Syndrome carriers from having future cancers
5 mei 2025 · 9 min
CEO Marina Udier describes the vaccine's design, what was presented at AACR, and discussions the company has had with U.S. FDA about running a registrational study. Plus, previewing upcoming data later this year in metastatic colorectal cancer.
-
Swiss Biotech Day: Molecular Partners' CEO and Swiss Biotech Association president Patrick Amstutz shares his take on biotech and previews what to expect from his U.S. listed company in 2025
5 mei 2025 · 13 min
He describes the clinical multi-specific T-cell engager program that will have data this year, and highlights the idea behind a next-generation logic-gating platform. Plus, entering the clinic with a DLL3 radio-DARPin and choosing mesothelin as a second target. Lees meer
-
At a reception on the eve of Swiss Biotech Day, Swiss Biotech Association CEO Michael Altorfer introduces us to the conference and shares his thoughts on the state of biotech and global collaboration
4 mei 2025 · 8 min
He describes the goals of Swiss Biotech Day, explains how the Swiss biotech sector is funded more by private investment than perhaps other geographies, and discusses current events.
-
Biotech investor Thilo Schroeder of Nextech Invest shares his take on biotech and discusses portfolio companies Revolution Medicines, Tubulis, and Circle Pharma
2 mei 2025 · 24 min
He describes the history of Nextech, including being an early investor in Blueprint Medicines and Peloton, and discusses the importance of investing in companies that have a wide moat to protect from today's fierce global competition.
-
VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs.
2 mei 2025 · 12 min
Xlife Sciences CEO Oliver Baumann introduces us to the fund, which is publicly traded in Switzerland, while VERAXA CEO Christoph Antz describes the BiTAC AND-gating platform the company uses to improve on the precision of T-cell engagers and antibody-drug conjugates. Lees meer
-
Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries
1 mei 2025 · 15 min
Co-Founder & CEO Daniela Marino describes why CUTISS believes denovoSKIN is superior to autografting. She describes how they make it, walks us through the company's on-site GMP facility, and she discusses the clinical experience to date. The therapy is already in a phase 3 study in Europe. Lees meer
-
London based Baseimmune shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will use its AI platform to discover and develop new vaccines
29 april 2025 · 12 min
Co-founder & CEO Joshua Blight talks about Baseimmune's platform, which was inspired by the work that happened during COVID both in the UK and abroad. The company's current focus is on COVID and malaria.
-
Creyon Bio today announced a collaboration to help Lilly use its AI-powered oligo engineering platform and aptamer-based delivery approach to discover and develop therapies in a range of diseases
29 april 2025 · 11 min
Recently named CEO Serge Messerlian, who was previously CEO of Teon Therapeutics and President of Janssen Oncology, describes the platform behind this deal, which came with an upfront payment/investment of $13 million.
-
London based Laverock shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will be doing its work on programmable gene silencing
29 april 2025 · 12 min
CEO David Venables describes Laverock's platform that repurposed miRNA to reprogram cells in a highly specific way. It's own lead programs will be in oncology and regenerative medicine.
-
The London BioScience Innovation Centre (LBIC) today launched its new Apex Building lab space facility for biotech companies in the heart of the Kings Cross Knowledge Quarter
29 april 2025 · 10 min
Dr. Rich Ferrie gives BiotechTV a preview of the new facilities and describes how it is aimed for growing companies that have already achieved a series A or B. It has started at 37% occupancy on launch day.
-
Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies
25 april 2025 · 19 min
CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and Foghorn's independent programs targeting CBP, EP300, and ARID1B.
-
Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy
25 april 2025 · 29 min
She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient population is heterogenous in how they are affected by the disease. Plus, a description of Epicrispr's epigenome approach to science, and her personal relationship to facioscapulohumeral muscular dystrophy. Lees meer
-
Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on ACM, and more
23 april 2025 · 18 min
He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a clinical trial for accelerated approval by early 2026. Plus, how we should expect more ACM data in 2025.
-
Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides
23 april 2025 · 24 min
He describes how Metsera, which had its IPO two months ago, is aiming to develop a differentiated GLP-1 vs currently marketed products by having a lower dose and longer half-life. We discuss all the hot button issues in the obesity space today.
-
On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73
17 april 2025 · 17 min
He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes being Fc silent will allow Arcus to succeed in TIGIT where others have failed, and a CD73 program that is enrolling very quickly in pancreatic cancer. Lees meer
-
As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact
16 april 2025 · 13 min
CSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research circles. Plus, his take on what regulatory reforms could help U.S. competitiveness, and areas of research that excite him today. Lees meer
-
Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies
16 april 2025 · 11 min
Founder and CEO Nicole Paulk describes the process, which allows the public to invest as little as $100, and why she views the investors that come with it as an asset for her company.
-
Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)
15 april 2025 · 16 min
CEO Rick Winningham describes the science behind ampreloxetine, and the rationale for developing it for patients with multiple system atrophy. A commercial stage company that already receives income from two therapies (YUPELRI and TRELEGY), Theravance Biopharma's future direction and focus will be determined by the outcome of this key trial. Lees meer
-
Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target
15 april 2025 · 17 min
CEO Josh Lehrer and CSO Ethan Weiss describe the biology of the target and highlight the topline data, which was first announced at #JPM25. Plus, details on a new program targeting acromegaly.
-
After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor
14 april 2025 · 19 min
Co-Founder & CEO Sek Kathiresan walks us through the data, which so far has showed a clean safety profile and an impressive ability to lower LDL by over 50% in patients with a genetic form of hypercholesterolemia.
-
Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why
10 april 2025 · 12 min
Dr. Schlessinger descrbies how the new center is meant to speed up drug discovery work and enable Mount Sinai researchers to develop molecules that are more dynamic and with a higher success rate. It might also enable them to take drug development further than they traditionally have before. Lees meer
-
Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover
10 april 2025 · 14 min
They discusses takeaways from the conference, and comment on Beam, Korro, Wave, Intellia, Prime, Janux, Alto Nuero, Rapport, and YmAbs.
-
Jones Healthcare & Technology Innovation Conference: Pharvaris is developing oral bradykinin B2 receptor inhibitors for HEA - with a first pivotal scheduled to read in less than a year
10 april 2025 · 8 min
CFO David Nassif describes the unmet need that still exists today in HAE, and updates us on programs in both the acute and prophylactic settings.
-
Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June
10 april 2025 · 14 min
He describes where this fits into the ROS1 space, and the data that has been derived for the filing. Plus, mIDH1, drug-drug-conjugates, and his take on the current environment in biotech.
-
Jones Healthcare & Technology Innovation Conference: Wave CEO Paul Bolno discusses recent DMD data and regulatory feedback, and shares updates on alpha-1 antitrypsin, obesity, and Huntington's
10 april 2025 · 15 min
He describes the 48 week data for the exon 53 DMD program, and discusses the company's plan to seek accelerated approval. Plus, guidance on when to expect clinical updates on other programs.
-
Jones Healthcare & Technology Innovation Conference: The CIO of XOMA Royalty describes the inner workings of the royalty business, and also how to help with biotech's negative enterprise problem
9 april 2025 · 16 min
Brad Sitko describes how XOMA is able to do smaller deals than other larger investors in this space, and he gives examples of investments they have made. Plus how to help with the "zombie biotech" problem in some corners of the sector.
-
Jones Healthcare & Technology Innovation Conference: Trevi Therapeutics CEO Jennifer Good describes recent positive data in refractory chronic cough and previews upcoming IPF data
9 april 2025 · 11 min
She describes how the mechanism of Haduvio differs from other programs in chronic cough, and covers the recent phase 2a RIVER data.
-
Jones Healthcare & Technology Innovation Conference: Jones Research analysts Catherine Novack and Debanjana Chatterjee share their take on biotech and comment on companies they cover
9 april 2025 · 10 min
They discusses the macro and regulatory factors that have affected the sector so strongly, and comment on Wave, Korro, ProQr, Capricor, Trevi, and Kalvista.
-
Analyst Thursdays: Stifel's Alex Thompson updates us on the latest news and upcoming catalysts in the I&I space
4 april 2025 · 16 min
He shares his take on biotech and discusses argenx, Immunovant, AnaptysBio, Apogee, Dianthus, and Viridian.
-
Anglo Nordic Life Science Conference: The CEO of Cure Parkinson's talks about their work, and participating in the International Linked Clinical Trials Initiative
3 april 2025 · 5 min
CEO Helen Matthews describes the types of medicines they are supporting for clinical trials (including Ambroxol and GLP-1s), and folding a few programs into a dynamic, international consortium.
-
Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants
3 april 2025 · 9 min
Co-Founder and CEO Thomas Kledal describes the science behind this platform and program. Plus, how having access to donated kidneys is helping the company with its translational work.
-
On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress
3 april 2025 · 13 min
CEO Jason Gardner describes Ampersand's platform that is designed to make medicines act at the site of disease. He also shares updates on partnerships with Pfizer and Pioneering Medicines, and highlights work in obesity, immuno-inflammation and immuno-oncology. Lees meer
-
BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round
2 april 2025 · 11 min
CEO Nicki Thompson describes why she believes the company is differentied in the field, and how TRIMTECH's construct is designed to selectively degrade aggregates that cause neurodegeneration.
-
Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office
2 april 2025 · 10 min
He describes his background in life sciences investing and shares his take on the current state of the sector.
-
After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection
2 april 2025 · 14 min
He describes why a 'one-size-fits-all' approach has caused numerous ophthalmology trials to fail in the past, and why Character believes a precision medicine approach is overdue.
-
BioTrinity 2025: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed
1 april 2025 · 12 min
He describes the science behind the platform, which is already being used by Boehringer Ingelheim for cystic fibrosis. AlveoGene has plans to use it for conditions like the surfactant protein deficiencies SP-B & ABCA3, alpha-1 antitrypsin deficiency, and IPF. Lees meer
-
Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry
27 maart 2025 · 14 min
Founder and CEO Carlos Bustamante tells BiotechTV's AI Correspondent, Ryan Flinn, about the biobank and why it is important to better understand how diseases can have different profiles across diverse populations. Plus, how AI will play a role in this work. Lees meer
-
State of Possible: Winner of the MassBioDrive Startup of the Year Award last year, the Co-Founder and CEO of Eascra Biotech describes developing nanoparticles as a delivery vehicle for therapies
27 maart 2025 · 11 min
Mari Anne Snow describes the advantages she sees nanoparticles having over current modalities like viral vectors, LNPs, and others.
-
State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies
26 maart 2025 · 4 min
He describes the 14th fund that Atlas raised at the end of last year, which was $450 million. Plus, his take on the environment, regulatory changes, China's impact on the sector, and improving biopharma's image.
-
State of Possible: On the one-year anniversary of the spin-out of Seaport Therapeutics, Daphne Zohar describes the Glyph platform that powers it, and her thoughts on running depression trials
26 maart 2025 · 8 min
She describes the idea of leveraging Glyph to achieve oral dosing of medicines in cases where it would not be possible or tolerable. Plus, the lead clinical program, allopregnanolone, how the company thinks about avoiding high placebo responses in trials, and other programs. Lees meer
-
State of Possible: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech
26 maart 2025 · 13 min
He describes the nine patient dose ascending data in AAT deficiency that was historic for being the industry's first in-vivo proof of concept of a gene editor. Plus, what's next for that program and sickle cell, and the decision to do an "over the wall" financing. Lees meer
-
State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics
26 maart 2025 · 13 min
She describes the science behind chromatin and gene regulation, previews upcoming preclinical data the company will have at AACR for its lead SMARCA2 program (partnered with Lilly), and discusses what she would like to see out of future phase 1 data.
-
State of Possible: Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company's programs, including a new one to come
26 maart 2025 · 12 min
He gives a brief overview of this approach, comments on recent competitor data in cancer, and highlights Kymera's STAT6 and TYK2 programs.
-
State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more
26 maart 2025 · 6 min
She describes the efforts that government is making to support medical research in the area, shares her thoughts on competition in science and for jobs from China, and her thoughts on how the industry can improve its messaging.
-
State of Possible: Strand Therapeutics' Co-Founder & CEO Jake Becraft talks mRNA and getting into the clinic with the company's first program
26 maart 2025 · 13 min
He describes the intratumoral IL-12 program that is in the clinic today, and the preclinical progress Strand is making on its other programs. Plus, his thoughts on the current public perception of mRNA.
-
At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talked the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more
25 maart 2025 · 22 min
He described the discovery work that Alloy does with its client partners, and highlighted emerging areas of science. Plus, the importance of good murine models, and his take on Chinese competition.
-
Oxford, UK based Greywolf Therapeutics is pursuing cancer and autoimmune indications by attempting to target T-cells at their first signal of activation - an approach the company leads the field on
25 maart 2025 · 14 min
Co-Founder and CEO Peter Joyce describes the science behind this, including how the company's lead programs inhibit Endoplasmic Reticulum Associated Proteases (ERAPs). A clinical stage company, he describes Greywolf's clinical experience and fundraising history. Lees meer